

# Abdoulaye A Djimde

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7210740/publications.pdf>

Version: 2024-02-01

152  
papers

9,965  
citations

36203

51  
h-index

40881

93  
g-index

159  
all docs

159  
docs citations

159  
times ranked

7549  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Molecular Marker for Chloroquine-Resistant Falciparum Malaria. <i>New England Journal of Medicine</i> , 2001, 344, 257-263.	13.9	873
2	Pyrimethamine and Proguanil Resistance-Confering Mutations in <i>Plasmodium falciparum</i> Dihydrofolate Reductase: Polymerase Chain Reaction Methods for Surveillance in Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 1995, 52, 565-568.	0.6	577
3	Reemergence of Chloroquine-Sensitive <i>Plasmodium falciparum</i> Malaria after Cessation of Chloroquine Use in Malawi. <i>Journal of Infectious Diseases</i> , 2003, 187, 1870-1875.	1.9	453
4	Analysis of <i>Plasmodium falciparum</i> diversity in natural infections by deep sequencing. <i>Nature</i> , 2012, 487, 375-379.	13.7	450
5	Multiple populations of artemisinin-resistant <i>Plasmodium falciparum</i> in Cambodia. <i>Nature Genetics</i> , 2013, 45, 648-655.	9.4	424
6	Mutations in <i>Plasmodium falciparum</i> Dihydrofolate Reductase and Dihydropteroate Synthase and Epidemiologic Patterns of Pyrimethamine-Sulfadoxine Use and Resistance. <i>Journal of Infectious Diseases</i> , 1997, 176, 1590-1596.	1.9	395
7	Genome-wide and fine-resolution association analysis of malaria in West Africa. <i>Nature Genetics</i> , 2009, 41, 657-665.	9.4	345
8	Resistance to antifolates in <i>Plasmodium falciparum</i> monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. <i>Molecular and Biochemical Parasitology</i> , 1997, 89, 161-177.	0.5	237
9	malERA: An updated research agenda for malaria elimination and eradication. <i>PLoS Medicine</i> , 2017, 14, e1002456.	3.9	221
10	Polymorphisms in <i>Plasmodium falciparum</i> Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for <i>P. falciparum</i> Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 833-843.	0.6	204
11	K13-Propeller Polymorphisms in <i>Plasmodium falciparum</i> Parasites From Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2015, 211, 1352-5.	1.9	203
12	Tools and Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand Convergence in Malaria?. <i>PLoS Biology</i> , 2016, 14, e1002380.	2.6	185
13	Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. <i>Lancet, The</i> , 2001, 358, 890-891.	6.3	164
14	CLEARANCE OF DRUG-RESISTANT PARASITES AS A MODEL FOR PROTECTIVE IMMUNITY IN <i>PLASMODIUM FALCIPARUM</i> MALARIA. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 69, 558-563.	0.6	159
15	Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development. <i>Science Translational Medicine</i> , 2009, 1, 2ra5.	5.8	154
16	<i>Plasmodium malariae</i> and <i>P. ovale</i> genomes provide insights into malaria parasite evolution. <i>Nature</i> , 2017, 542, 101-104.	13.7	150
17	A barcode of organellar genome polymorphisms identifies the geographic origin of <i>Plasmodium falciparum</i> strains. <i>Nature Communications</i> , 2014, 5, 4052.	5.8	130
18	Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. <i>Lancet, The</i> , 2020, 396, 1829-1840.	6.3	128

#	ARTICLE	IF	CITATIONS
19	Impact of Trimethoprimâ€Sulfamethoxazole Prophylaxis on Falciparum Malaria Infection and Disease. <i>Journal of Infectious Diseases</i> , 2005, 192, 1823-1829.	1.9	119
20	Intermittent Preventive Treatment of Malaria Provides Substantial Protection against Malaria in Children Already Protected by an Insecticide-Treated Bednet in Mali: A Randomised, Double-Blind, Placebo-Controlled Trial. <i>PLoS Medicine</i> , 2011, 8, e1000407.	3.9	118
21	Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. <i>New England Journal of Medicine</i> , 2021, 385, 1005-1017.	13.9	114
22	Major subpopulations of <i>Plasmodium falciparum</i> in sub-Saharan Africa. <i>Science</i> , 2019, 365, 813-816.	6.0	105
23	Characterization of Within-Host <i>Plasmodium falciparum</i> Diversity Using Next-Generation Sequence Data. <i>PLoS ONE</i> , 2012, 7, e32891.	1.1	102
24	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	0.9	97
25	Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali. <i>PLoS Medicine</i> , 2007, 4, e93.	3.9	94
26	Understanding the pharmacokinetics of Coartem®. <i>Malaria Journal</i> , 2009, 8, S4.	0.8	94
27	Pyronaridineâ€artesunate or dihydroartemisininâ€piperazine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. <i>Lancet</i> , The, 2018, 391, 1378-1390.	6.3	93
28	Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study. <i>Lancet Haematology</i> , the, 2018, 5, e333-e345.	2.2	90
29	Polymorphisms in the K13-Propeller Gene in Artemisinin-Susceptible <i>Plasmodium falciparum</i> Parasites from Bougoula-Hameau and Bandiagara, Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 1202-1206.	0.6	89
30	Clearance of drug-resistant parasites as a model for protective immunity in <i>Plasmodium falciparum</i> malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 69, 558-63.	0.6	89
31	Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. <i>Blood</i> , 2000, 96, 2358-63.	0.6	84
32	Randomized, multicentre assessment of the efficacy and safety of ASAQ â€ a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria. <i>Malaria Journal</i> , 2009, 8, 125.	0.8	82
33	COVID-19: Shining the Light on Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 1145-1148.	0.6	78
34	Measuring the impact of seasonal malaria chemoprevention as part of routine malaria control in Kita, Mali. <i>Malaria Journal</i> , 2017, 16, 325.	0.8	74
35	Efficacy, Safety, and Selection of Molecular Markers of Drug Resistance by Two ACTs in Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 455-461.	0.6	69
36	An Effective Method to Purify <i>Plasmodium falciparum</i> DNA Directly from Clinical Blood Samples for Whole Genome High-Throughput Sequencing. <i>PLoS ONE</i> , 2011, 6, e22213.	1.1	68

#	ARTICLE	IF	CITATIONS
37	Community Pyrimethamine-Sulfadoxine Use and Prevalence of Resistant Plasmodium falciparum Genotypes in Mali: A Model for Deterring Resistance. American Journal of Tropical Medicine and Hygiene, 1996, 55, 467-471.	0.6	68
38	First Detection of Leishmania major DNA in Sergentomyia (Spelaeomyia) darlingi from Cutaneous Leishmaniasis Foci in Mali. PLoS ONE, 2012, 7, e28266.	1.1	66
39	Impact of pre-season treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali.. American Journal of Tropical Medicine and Hygiene, 2002, 67, 604-610.	0.6	66
40	Population Genetic Analysis of Plasmodium falciparum Parasites Using a Customized Illumina GoldenGate Genotyping Assay. PLoS ONE, 2011, 6, e20251.	1.1	63
41	Whole-Genome Scans Provide Evidence of Adaptive Evolution in Malawian Plasmodium falciparum Isolates. Journal of Infectious Diseases, 2014, 210, 1991-2000.	1.9	62
42	Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malaria Journal, 2014, 13, 483.	0.8	61
43	Superiority of 3 Over 2 Doses of Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine for the Prevention of Malaria During Pregnancy in Mali: A Randomized Controlled Trial. Clinical Infectious Diseases, 2011, 53, 215-223.	2.9	60
44	Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses. The Lancet Global Health, 2020, 8, e1499-e1511.	2.9	60
45	No Evidence of Delayed Parasite Clearance after Oral Artesunate Treatment of Uncomplicated Falciparum Malaria in Mali. American Journal of Tropical Medicine and Hygiene, 2012, 87, 23-28.	0.6	58
46	Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infectious Diseases, The, 2016, 16, 189-198.	4.6	58
47	Rapid Selection of Plasmodium falciparum Dihydrofolate Reductase Mutants by Pyrimethamine Prophylaxis. Journal of Infectious Diseases, 2000, 182, 993-996.	1.9	57
48	Monitoring and Deterring Drug-Resistant Malaria in the Era of Combination Therapy. American Journal of Tropical Medicine and Hygiene, 2007, 77, 160-169.	0.6	57
49	Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. American Journal of Tropical Medicine and Hygiene, 2008, 78, 455-61.	0.6	57
50	malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication. PLoS Medicine, 2017, 14, e1002450.	3.9	55
51	Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali.. American Journal of Tropical Medicine and Hygiene, 1999, 60, 475-478.	0.6	55
52	A Randomized Trial of Artesunate-Mefloquine versus Artemether-Lumefantrine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Mali. American Journal of Tropical Medicine and Hygiene, 2008, 79, 655-661.	0.6	55
53	Molecular Diagnosis of Resistance to Antimalarial Drugs during Epidemics and in War Zones. Journal of Infectious Diseases, 2004, 190, 853-855.	1.9	52
54	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	0.9	51

#	ARTICLE	IF	CITATIONS
55	Reducing the Carbon Footprint of Academic Conferences: The Example of the American Society of Tropical Medicine and Hygiene. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1758-1761.	0.6	48
56	Sulfadoxine-pyrimethamine impairs <i>Plasmodium falciparum</i> gametocyte infectivity and <i>Anopheles</i> mosquito survival. <i>International Journal for Parasitology</i> , 2010, 40, 1221-1228.	1.3	46
57	Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in two multi-country randomised clinical trials in African adults. <i>Malaria Journal</i> , 2014, 13, 458.	0.8	46
58	Genetic diversity and drug resistance surveillance of <i>Plasmodium falciparum</i> for malaria elimination: is there an ideal tool for resource-limited sub-Saharan Africa?. <i>Malaria Journal</i> , 2019, 18, 217.	0.8	46
59	Use of antimalarial drugs in Mali: policy versus reality.. <i>American Journal of Tropical Medicine and Hygiene</i> , 1998, 59, 376-379.	0.6	45
60	Conservation of a novel vacuolar transporter in <i>Plasmodium</i> species and its central role in chloroquine resistance of <i>P. falciparum</i> . <i>Current Opinion in Microbiology</i> , 2001, 4, 415-420.	2.3	44
61	The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem <sup>®</sup> ) for acute uncomplicated <i>Plasmodium falciparum</i> malaria. <i>Tropical Medicine and International Health</i> , 2010, 15, 434-41.	1.0	42
62	A review of the frequencies of <i>Plasmodium falciparum</i> Kelch 13 artemisinin resistance mutations in Africa. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2021, 16, 155-161.	1.4	42
63	Monitoring and deterring drug-resistant malaria in the era of combination therapy. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 160-9.	0.6	42
64	Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. <i>Malaria Journal</i> , 2010, 9, 9.	0.8	40
65	Monitoring parasite diversity for malaria elimination in sub-Saharan Africa. <i>Science</i> , 2014, 345, 1297-1298.	6.0	39
66	Dermatophytosis among Schoolchildren in Three Eco-climatic Zones of Mali. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004675.	1.3	39
67	Broadening Participation in the Sciences within and from Africa: Purpose, Challenges, and Prospects. <i>CBE Life Sciences Education</i> , 2017, 16, es2.	1.1	38
68	<i>In Vivo</i> and <i>In Vitro</i> Antimalarial Properties of Azithromycin-Chloroquine Combinations That Include the Resistance Reversal Agent Amlodipine. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3115-3124.	1.4	37
69	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. <i>BMC Medicine</i> , 2015, 13, 66.	2.3	37
70	Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. <i>Tropical Medicine and International Health</i> , 2009, 14, 784-791.	1.0	36
71	A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 655-61.	0.6	36
72	Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated <i>falciparum</i> malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. <i>Malaria Journal</i> , 2009, 8, 34.	0.8	35

#	ARTICLE	IF	CITATIONS
73	Low infectivity of <i>Plasmodium falciparum</i> gametocytes to <i>Anopheles gambiae</i> following treatment with sulfadoxine-pyrimethamine in Mali. <i>International Journal for Parasitology</i> , 2010, 40, 1213-1220.	1.3	34
74	Hematologic Parameters in Pediatric Uncomplicated <i>Plasmodium falciparum</i> Malaria in Sub-Saharan Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 85, 619-625.	0.6	34
75	Repeated Artemisinin-Based Combination Therapies in a Malaria Hyperendemic Area of Mali: Efficacy, Safety, and Public Health Impact. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 50-56.	0.6	32
76	Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali. <i>PLoS ONE</i> , 2016, 11, e0162718.	1.1	32
77	Molecular markers for artemisinin and partner drug resistance in natural <i>Plasmodium falciparum</i> populations following increased insecticide treated net coverage along the slope of mount Cameroon: cross-sectional study. <i>Infectious Diseases of Poverty</i> , 2017, 6, 136.	1.5	32
78	Chloroquine treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Mali: parasitologic resistance versus therapeutic efficacy.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2001, 64, 242-246.	0.6	32
79	A RANDOMIZED TRIAL OF ARTESUNATE-SULFAMETHOXYPIRAZINE-PYRIMETHAMINE VERSUS ARTEMETHER-LUMEFANTRINE FOR THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN MALI. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 630-636.	0.6	32
80	Reduced ex vivo susceptibility of <i>Plasmodium falciparum</i> after oral artemether-lumefantrine treatment in Mali. <i>Malaria Journal</i> , 2017, 16, 59.	0.8	27
81	Genetic determinants of anti-malarial acquired immunity in a large multi-centre study. <i>Malaria Journal</i> , 2015, 14, 333.	0.8	26
82	Expanding Research Capacity in Sub-Saharan Africa Through Informatics, Bioinformatics, and Data Science Training Programs in Mali. <i>Frontiers in Genetics</i> , 2019, 10, 331.	1.1	26
83	Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali. <i>Malaria Journal</i> , 2009, 8, 5.	0.8	25
84	A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Mali. <i>Malaria Journal</i> , 2018, 17, 347.	0.8	25
85	Pharmacokinetic and Pharmacodynamic Characteristics of a New Pediatric Formulation of Artemether-Lumefantrine in African Children with Uncomplicated <i>Plasmodium falciparum</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3994-3999.	1.4	24
86	A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 630-6.	0.6	24
87	PlasmoView: A Web-based Resource to Visualise Global <i>Plasmodium falciparum</i> Genomic Variation. <i>Journal of Infectious Diseases</i> , 2014, 209, 1808-1815.	1.9	23
88	Baseline in vitro efficacy of ACT component drugs on <i>Plasmodium falciparum</i> clinical isolates from Mali. <i>International Journal for Parasitology</i> , 2008, 38, 791-798.	1.3	22
89	A molecular map of chloroquine resistance in Mali. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 58, 113-118.	2.7	21
90	Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger. <i>BMC Medicine</i> , 2016, 14, 167.	2.3	21

#	ARTICLE	IF	CITATIONS
91	Time for malaria control in school-age children. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 537-538.	2.7	21
92	Efficacy of artesunate + amodiaquine, dihydroartemisinin + piperazine and artemether + lumefantrine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Maradi, Niger. <i>Malaria Journal</i> , 2018, 17, 52.	0.8	20
93	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. <i>PLoS Medicine</i> , 2020, 17, e1003040.	3.9	20
94	<i>Plasmodium falciparum</i> field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype. <i>Infection, Genetics and Evolution</i> , 2015, 30, 318-322.	1.0	18
95	Expression of complement and toll-like receptor pathway genes is associated with malaria severity in Mali: a pilot case control study. <i>Malaria Journal</i> , 2016, 15, 150.	0.8	18
96	In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxine + Pyrimethamine Versus Artemether + Lumefantrine in Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 634-639.	0.6	18
97	Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in HoundÃ© District, Burkina Faso and Bougouni District, Mali. <i>PLoS Medicine</i> , 2020, 17, e1003214.	3.9	18
98	Molecular Detection of Microorganisms Associated with Small Mammals and Their Ectoparasites in Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2542-2551.	0.6	18
99	Efficacy of chloroquine and sulfadoxine/pyrimethamine for the treatment of uncomplicated <i>falciparum</i> malaria in Koumantou, Mali. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2006, 100, 1013-1018.	0.7	16
100	Different <i>Plasmodium falciparum</i> clearance times in two Malian villages following artesunate monotherapy. <i>International Journal of Infectious Diseases</i> , 2020, 95, 399-405.	1.5	16
101	A comparison of anemia in hemoglobin C and normal hemoglobin A children with <i>Plasmodium falciparum</i> malaria. <i>Acta Tropica</i> , 2004, 90, 295-299.	0.9	15
102	Comparison of azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in children in Africa: a randomized, open-label study. <i>Malaria Journal</i> , 2015, 14, 108.	0.8	15
103	Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children. <i>Journal of Clinical Virology</i> , 2016, 77, 40-45.	1.6	15
104	Gametocyte clearance dynamics following oral artesunate treatment of uncomplicated <i>falciparum</i> malaria in Malian children. <i>Parasite</i> , 2016, 23, 3.	0.8	14
105	Artemisinin-based combination therapy for uncomplicated <i>Plasmodium falciparum</i> malaria in Mali: a systematic review and meta-analysis. <i>Malaria Journal</i> , 2021, 20, 356.	0.8	14
106	The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1031-1045.	2.0	13
107	Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of <i>Plasmodium falciparum</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4366-4374.	1.4	13
108	High frequency of PfCRT 76T in two Malian villages and its prevalence in severe relative to non-severe malaria. <i>Acta Tropica</i> , 2011, 119, 11-13.	0.9	12

#	ARTICLE	IF	CITATIONS
109	Standardised versus actual white cell counts in estimating thick film parasitaemia in African children under five. <i>Tropical Medicine and International Health</i> , 2011, 16, 551-554.	1.0	12
110	<i>Toxoplasma gondii</i> Seroprevalence in Mali. <i>Journal of Parasitology</i> , 2013, 99, 371-374.	0.3	12
111	Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali. <i>Malaria Journal</i> , 2015, 14, 64.	0.8	12
112	Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1450-1458.	1.4	12
113	Haemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa. <i>BMC Infectious Diseases</i> , 2017, 17, 443.	1.3	12
114	Zika Virus Circulation in Mali. <i>Emerging Infectious Diseases</i> , 2020, 26, 945-952.	2.0	11
115	Surveillance of Travellers: An Additional Tool for Tracking Antimalarial Drug Resistance in Endemic Countries. <i>PLoS ONE</i> , 2013, 8, e77775.	1.1	11
116	Effect of three years' seasonal malaria chemoprevention on molecular markers of resistance of <i>Plasmodium falciparum</i> to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali. <i>Malaria Journal</i> , 2022, 21, 39.	0.8	11
117	Host candidate gene polymorphisms and clearance of drug-resistant <i>Plasmodium falciparum</i> parasites. <i>Malaria Journal</i> , 2011, 10, 250.	0.8	10
118	Prevalence of malaria and factors associated with infection in children aged 6 months to 9 years in Guinea: Results from a national cross-sectional study. <i>Parasite Epidemiology and Control</i> , 2020, 11, e00162.	0.6	10
119	Targeted Next Generation Sequencing for malaria research in Africa: current status and outlook. <i>Malaria Journal</i> , 2019, 18, 324.	0.8	9
120	Seroprevalence and Parasite Rates of <i>Plasmodium malariae</i> in a High Malaria Transmission Setting of Southern Nigeria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2208-2216.	0.6	9
121	Epidemiology of the outbreak, vectors and reservoirs of cutaneous leishmaniasis in Mali: A systematic review and meta-analysis. <i>Asian Pacific Journal of Tropical Medicine</i> , 2016, 9, 985-990.	0.4	8
122	Analyzing Deoxyribose Nucleic Acid from Malaria Rapid Diagnostic Tests to Study <i>Plasmodium falciparum</i> Genetic Diversity in Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 1259-1265.	0.6	7
123	<i>Listeria monocytogenes</i> in human milk in Mali: A potential health emergency. <i>Journal of Infection</i> , 2020, 80, 121-142.	1.7	7
124	Selection of pfcr1 K76 and pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in Mali. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6057.	1.8	7
125	Persistent Submicroscopic <i>Plasmodium falciparum</i> Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0087321.	1.4	7
126	Differential infectivity of gametocytes after artemisinin-based combination therapy of uncomplicated falciparum malaria. <i>African Journal of Laboratory Medicine</i> , 2018, 7, 784.	0.2	7



#	ARTICLE	IF	CITATIONS
127	Challenges in the clinical development pathway for triple and multiple drug combinations in the treatment of uncomplicated falciparum malaria. <i>Malaria Journal</i> , 2022, 21, 61.	0.8	7
128	Impact of Three-Year Intermittent Preventive Treatment Using Artemisinin-Based Combination Therapies on Malaria Morbidity in Malian Schoolchildren. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 148.	0.9	6
129	A Double-Blind Randomized Placebo-Controlled Clinical Trial of Squalamine Ointment for tinea capitis Treatment. <i>Mycopathologia</i> , 2015, 179, 187-193.	1.3	5
130	A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study. <i>BMC Infectious Diseases</i> , 2015, 15, 228.	1.3	5
131	Two-Year Scale-Up of Seasonal Malaria Chemoprevention Reduced Malaria Morbidity among Children in the Health District of Koutiala, Mali. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6639.	1.2	5
132	Epitope-based sieve analysis of <i>Plasmodium falciparum</i> sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants. <i>Vaccine</i> , 2020, 38, 5700-5706.	1.7	5
133	Uptake of <i>Plasmodium falciparum</i> Gametocytes During Mosquito Bloodmeal by Direct and Membrane Feeding. <i>Frontiers in Microbiology</i> , 2020, 11, 246.	1.5	5
134	Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether-lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso. <i>Malaria Journal</i> , 2021, 20, 64.	0.8	4
135	<i>Plasmodium malariae</i> and <i>Plasmodium falciparum</i> comparative susceptibility to antimalarial drugs in Mali. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2079-2087.	1.3	4
136	<i>Virgibacillus doumboii</i> sp. nov., a halophilic bacterium isolated from the stool of a healthy child in Mali. <i>New Microbes and New Infections</i> , 2021, 42, 100890.	0.8	4
137	The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003766.	3.9	4
138	Selection of Pfcr1 76T and Pfmdr1 86Y Mutant <i>Plasmodium falciparum</i> after Treatment of Uncomplicated Malaria with Artesunate-Amodiaquine in Republic of Guinea. <i>Journal of Parasitology</i> , 2021, 107, 778-782.	0.3	4
139	Prevalence of Parasitic Infections in Children of Boke, Guinea. <i>Journal of Parasitology</i> , 2021, 107, 783-789.	0.3	4
140	Ex Vivo <i>Plasmodium malariae</i> Culture Method for Antimalarial Drugs Screen in the Field. <i>ACS Infectious Diseases</i> , 2021, 7, 3025-3033.	1.8	4
141	Model-based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a serological cross-reactivity context. <i>Nature Communications</i> , 2021, 12, 6735.	5.8	4
142	Relationship between weight status and anti-malarial drug efficacy and safety in children in Mali. <i>Malaria Journal</i> , 2019, 18, 40.	0.8	3
143	Draft Genome Sequence of <i>Bacillus velezensis</i> Strain Marseille-Q1230, Isolated from a Stool Sample from a Severely Malnourished Child. <i>Microbiology Resource Announcements</i> , 2021, 10, e0051421.	0.3	3
144	Tackling malaria transmission at a single cell level in an endemic setting in sub-Saharan Africa. <i>Nature Communications</i> , 2022, 13, 2679.	5.8	3

#	ARTICLE	IF	CITATIONS
145	Differential Incidence of Malaria in Neighboring Villages in a High-Transmission Setting of Southern Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1209-1214.	0.6	2
146	Cooperation in Countering Artemisinin Resistance in Africa: Learning from COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	0.6	2
147	An In Silico Analysis of Malaria Pre-Erythrocytic-Stage Antigens Interpreting Worldwide Genetic Data to Suggest Vaccine Candidate Variants and Epitopes. <i>Microorganisms</i> , 2022, 10, 1090.	1.6	2
148	Pharmacokinetic and Pharmacodynamic Characteristics of a New Pediatric Formulation of Artemether-Lumefantrine in African Children with Uncomplicated <i>Plasmodium falciparum</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5429-5429.	1.4	1
149	Monitoring of the Sensitivity In Vivo of <i>Plasmodium falciparum</i> to Artemether-Lumefantrine in Mali. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 13.	0.9	1
150	Sequencing SARS-CoV-2 in a Malaria Research Laboratory in Mali, West Africa: The Road to Sequencing the First SARS-CoV-2 Genome in Mali. <i>Processes</i> , 2021, 9, 2169.	1.3	1
151	Professor Ogobara K. Doumbo (1956â€“June 9, 2018). <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 1118-1119.	0.6	0
152	Building a center of excellence in biomedical research in an unfavorable environment: the Malaria Research and Training Center in Mali. <i>Medecine Et Sante Tropicales</i> , 2019, 29, 343-347.	0.3	0